CWNM News Out! Crown Marketing Takes Aim at Diabetes Medication

CHAPEL HILL, NC, Jan 31, 2013 (MARKETWIRE via COMTEX) -- Crown Marketing (OTCQB: CWNM) is pleased to announce that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. As the accompanying image indicates, Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin. The most common adverse effects of Metformin are gastrointestinal upset including diarrhea, cramps, nausea and vomiting. Crown believes it can significantly reduce or eliminate these effects with its patented technology.